See more : Phoenix Canada Oil Company Limited (PHXCF) Income Statement Analysis – Financial Results
Complete financial analysis of MeiraGTx Holdings plc (MGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MeiraGTx Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Ultra Lithium Inc. (ULT.V) Income Statement Analysis – Financial Results
- 88 Energy Limited (88E.AX) Income Statement Analysis – Financial Results
- Clariant AG (CLN.SW) Income Statement Analysis – Financial Results
- Minerals 260 Limited (MI6.AX) Income Statement Analysis – Financial Results
- Danske Invest Euro HY-Obl – Akk (DKIEUHYOAKKDKKH.CO) Income Statement Analysis – Financial Results
MeiraGTx Holdings plc (MGTX)
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 8.72M | 7.87M | 0.00 | 0.00 | 2.05M | 679.18K | 243.08K |
| Gross Profit | 14.02M | 7.20M | 29.83M | 15.56M | 13.29M | -2.05M | -679.18K | -243.08K |
| Gross Profit Ratio | 100.00% | 45.21% | 79.12% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.79M | 85.73M | 67.13M | 33.91M | 24.88M | 33.62M | 22.36M | 14.04M |
| General & Administrative | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Other Expenses | 0.00 | 361.00K | -434.00K | 0.00 | 0.00 | 83.08K | -553.50K | 0.00 |
| Operating Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Cost & Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Interest Income | 2.27M | 777.00K | 212.00K | 1.28M | 370.60K | 53.41K | 26.07K | 32.07K |
| Interest Expense | 13.25M | 4.95M | 288.00K | 139.20K | 48.61K | 33.43K | 42.86K | 25.44K |
| Depreciation & Amortization | 13.73M | 8.72M | 7.87M | 4.17M | 3.35M | 2.05M | 679.18K | 243.08K |
| EBITDA | -57.05M | -115.95M | -71.40M | -53.68M | -51.35M | -78.10M | -31.01M | -19.82M |
| EBITDA Ratio | -407.02% | -725.99% | -193.58% | -393.75% | -435.58% | 0.00% | 0.00% | 0.00% |
| Operating Income | -137.06M | -116.36M | -73.19M | -62.55M | -58.27M | -78.10M | -31.68M | -20.06M |
| Operating Income Ratio | -977.82% | -730.87% | -194.14% | -401.94% | -438.37% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.03M | -13.26M | -6.37M | 4.56M | 3.52M | -5.24M | 640.19K | 272.17K |
| Income Before Tax | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M | -19.79M |
| Income Before Tax Ratio | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.26M | -7.59M | -4.03M | -2.19M | -474.39K | -510.64K | -280.44K |
| Net Income | -84.03M | -142.88M | -71.98M | -53.96M | -52.56M | -82.87M | -31.04M | -19.49M |
| Net Income Ratio | -599.46% | -897.46% | -190.91% | -346.72% | -395.40% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| EPS Diluted | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| Weighted Avg Shares Out | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
| Weighted Avg Shares Out (Dil) | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates
A Biotech Unveils Its New Gene Control Technology
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
MeiraGTx to Participate in Upcoming Virtual Investor Conferences
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline
MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa
MeiraGTx Reports Second Quarter 2021 Financial and Operational Results
Source: https://incomestatements.info
Category: Stock Reports